Whole body 18F-FDG pet predicts progression free and overall survival in squamous cell carcinoma of the esophagus: Results of a prospective trial

Hematology/ Oncology and Stem Cell Therapy

Volumn 3, Issue 4, 2010, Pages 179-184

  Abdelsalam, Mahmoud ^a   Bazarbashi, Shouki ^a   Abouzied, Moheieldin ^a   Amin, Tarek ^a   Soudy, Hussein ^a   Rahal, Mohamed ^a   Darwish, Alaa ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; WHOLE BODY IMAGING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; WHOLE BODY IMAGING;

EID: 79952033479     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2010.179     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Daly JM, Karnell LH, Menck HR. National Canccer Data Base report on esophageal carcinoma. Cancer 1996; 78: 1820-8.
3. Sagar PM, Gauperaa T, Sue-Ling H, McMahon MJ, Johnston D. An audit of the treatment of canccer of the oesophagus. Gut 1994; 35: 941-5.
4. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in Esophageal Cancer. Incremental Value over Computed Tomogrraphy. Clin Positron Imaging 1999; 2: 255-60.
5. Ajani JA. Current status of new drugs and multtidisciplinary approaches in patients with carcinnoma of the esophagus. Chest 1998; 113: 112S-9S.
6. Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentggenol 1997; 168: 417-24.
7. Darnton SJ, Archer VR, Stocken DD, Mulholland PJ Casson AG, Ferry DR. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagecttomy in squamous cell carcinoma of the esophaggus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol 2003; 21: 4009-15.
8. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K et al. Metabolic imaging predicts response, survival, and recurrence in adenocarccinomas of the esophagogastric junction. J Clin Oncol 2006; 24: 4692-8.
9. Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202-10.
10. Bazarbashi S, Abdelsalam M, Amin T, El-Bassiouni M, Soudy H, Elweshi A et al. Phase IItrial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carccinoma of the esophagus. Chemotherapy 2008; 54: 315-22.
11. Kelsen D. Adjuvant therapy of upper gastrointesttinal tract cancers. Semin Oncol 1991; 18: 543-59.
12. Brucher BL, Stein HJ, Zimmermann F, Werner M, Sarbia M, Busch R et al. Responders benefit from neoadjuvant radiochemotherapy in esophaggeal squamous cell carcinoma: results of a prosspective phase-IItrial. Eur J Surg Oncol 2004; 30: 963-71.
13. Brucher WH, Lordick F, Becker K, Weiss BR, Stein H, Molls M et al. Final report of assessmment of response to neoadjuvant radiochemottherapyin esophageal squamous cell carcinoma patients by 18-FDG-PET. J Clin Gastroenterol 2006; 40 Suppl 4.
14. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, et al. Positron emisssion tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002; 13: 361-8.
15. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M et al. Whole body 18FDG-PET and the response of esophageal cancer to inducttion therapy: results of a prospective trial. J Clin Oncol 2003; 21: 428-32.
16. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R et al. Utility of PET, CT, and EUS to identify pathologic responders in esophaggeal cancer. Ann Thorac Surg 2004; 78: 1152-1160; discussion 1152-60.
17. Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 2006; 82: 391-394; discussion 394-5.
18. Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tommography in oesophageal cancer for prediction of pathologic response and survival after preopeerative chemoradiotherapy. Eur J Cancer 2007; 43: 1385-91.
19. Port JL, Lee PC, Korst RJ, Liss Y, Meherally D, Christos P et al. Positron emission tomographic scanning predicts survival after induction chemottherapy for esophageal carcinoma. Ann Thorac Surg 2007; 84: 393-400.
20. Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I et al. Positron emission tommography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus 2008; 21: 151-8.
21. Lordick F, Ruers T, Aust DE, Collette L, Downey RJ, El Hajjam M, Flamen P, Haustermans K, Ilson D, Julié C, Krause BJ, Newiger H, Ott K, Roth A, Van Cutsem E, Weber WA, Lutz MP; European Orgganisation of Research and Treatment of Cancer Gastrointestinal Group. European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 2008; 44: 1807-1819.
22. Flamen P, Lerut T, Haustermans K, Van Cutsem E, Mortelmans L. Position of positron emission tommography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imaging 2004; 48: 96-108.
23. Rizk N, Downey RJ, Akhurst T, Gonen M, Bains MS, Larson S, Rusch V. Preoperative 18[F]-Fluorrodeoxyglucose Positron Emission Tomography Standardized Uptake Values Predict Survival Aftter Esophageal Adenocarcinoma Resection. Ann Thorac Surg 2006;81:1076-82.